摘要
目的:本研究探讨中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)与接受肝动脉栓塞化疗(transarterial chemoembolization,TACE)肝癌(hepatocellular carcinoma,HCC)患者术后生存期的相关性。方法:回顾性分析2007年1月至2015年6月中山大学肿瘤防治中心肝胆胰科确诊为肝癌并行TACE治疗的216例患者。研究患者依照NLR和PLR的界值分成两组。分析并比较NLR和PLR在不同随访时间点的受试者工作曲线(ROC)下面积。单因素和多因素分析用于评价NLR和PLR与TACE术后肝癌患者预后的相关性。结果:本研究中位随访时间为431.1 d。全体研究对象1、2、3年生存率分别为61.3%、44.2%和40.5%。中位生存时间为410.5 d。术前NLR<1.77组和术前NLR≥1.77组1、2、3年生存率分别为81.6%、63.0%、45.7%和43.1%、27.0%、19.3%,差异具有统计学意义(P<0.001)。术前PLR<94.62组和术前PLR≥94.62组1、2、3年生存率分别为62.7%、47.0%、37.0%和46.8%、29.0%、18.5%,差异具有统计学意义(P=0.002)。多因素分析显示NLR≥1.77与TACE术后肝癌患者较差预后相关,是肝癌患者TACE治疗后的危险因素。结论:TACE介入术前HCC患者的NLR水平,作为系统炎症的一个反应指标,是影响其预后的危险因素。
Objective：To identify the correlation between neutrophil to lymphocyte ratio （NLR）, platelet to lymphocyte ratio （PLR）, and hepatocellular carcinoma （HCC） patients who underwent transarterial chemoembolization （TACE）. Methods： We retrospectively re-viewed 216 patients who were diagnosed with HCC and treated with TACE between January 2007 and June 2015 at the Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University. The patients were stratified into two groups using NLR and PLR cutoff values. NLR and PLR were analyzed and compared through the area under receiver operating characteristic curves at different time points. Univariate and multivariate analyses were applied to evaluate the correlation between NLR, PLR, and HCC patients who were treated with TACE. Results：The median follow-up period was 431.11 d. The estimated 1-, 2-, and 3-year overall survival （OS） rates were 61.3%, 44.2%, and 40.5%for the entire study cohort, respectively. The median OS was 410.5 d. The estimated 1-, 2-, and 3-year OS rates for NLR〈1.77 group and NLR≥1.77 group were 81.6%, 63.0%, and 45.7%;and 43.1%, 27.0%, and 19.3%, respectively. The dif-ference was significant （P〈0.001）. The estimated 1-, 2-, and 3-year OS rates for PLR〈94.62 group and PLR≥94.62 group were 62.7%, 47.0%, and 37.0%;and 46.8%, 29.0%, and 18.5%, respectively. The difference was significant （P=0.002）. In a multivariate analysis, NLR≥1.77 was a risk factor associated with poor outcome for patients with HCC who received TACE therapy. Conclusion：NLR level be-fore TACE is an indicator of systemic inflammation and is a risk factor associated with the prognosis of HCC patients who were treated with TACE.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2017年第6期283-288,共6页
Chinese Journal of Clinical Oncology
